MAI Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.3K | Sell |
19,054
-45,337
| -70% | -$41.1K | ﹤0.01% | 2264 |
|
|
2025
Q1 | $29.1K | Sell |
64,391
-593,288
| -90% | -$268K | ﹤0.01% | 1903 |
|
|
2024
Q4 | $330K | Sell |
657,679
-1,017,000
| -61% | -$511K | ﹤0.01% | 925 |
|
|
2024
Q3 | $1.52M | Buy |
1,674,679
+35,907
| +2% | +$32.5K | 0.01% | 444 |
|
|
2024
Q2 | $1.63M | Buy |
1,638,772
+147,910
| +10% | +$148K | 0.02% | 448 |
|
|
2024
Q1 | $2.21M | Buy |
1,490,862
+687,017
| +85% | +$1.02M | 0.02% | 377 |
|
|
2023
Q4 | $876K | Sell |
803,845
-150,843
| -16% | -$164K | 0.01% | 488 |
|
|
2023
Q3 | $1.13M | Buy |
954,688
+3,110
| +0.3% | +$3.67K | 0.02% | 400 |
|
|
2023
Q2 | $1.34M | Buy |
951,578
+526,463
| +124% | +$742K | 0.02% | 368 |
|
|
2023
Q1 | $638K | Sell |
425,115
-31,702
| -7% | -$47.6K | 0.01% | 545 |
|
|
2022
Q4 | $534K | Sell |
456,817
-65,053
| -12% | -$76.1K | 0.01% | 586 |
|
|
2022
Q3 | $590K | Buy |
521,870
+274,135
| +111% | +$310K | 0.01% | 490 |
|
|
2022
Q2 | $391K | Buy |
+247,735
| New | +$391K | 0.01% | 594 |
|